Randomized trial finds that lenacapavir PrEP implementation experiences delays in initiation and impact on persistence in diverse settings, indicating areas for improvement.
Lenacapavir PrEP implementation across 17 U.S. sites (n=501) was characterized by delays in initiation driven by payer processes. Early non-persistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable clinical and structural barriers to early persistence.
No takes yet. Share an insight, caveat, or question.
Hazra et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: